The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS)


The purpose of this study is to evaluate the effects of nutritional supplementation with omega-9 "olive-oil" and omega-6 "soybean oil" based lipid emulsions in the Acute Respiratory Distress Syndrome (ARDS). The investigators hypothesize that these specific lipids in combination will immunomodulate the inflammatory reaction that occurs in the lungs of ARDS subjects. This concept is known as "Pharmaconutrition." These lipids will be given intravenously so as to assure administration and only as a supplement to enteral nutrition which all subjects will also receive. The omega-9 will be compared to the omega-6 formulation which is the only FDA approved formulation of use in the United States since its development in 1961 by Fresenius-Kabi, Bad Homburg, Germany. The investigators plan to perform a bronchoscopy with lavage within 24 hours of enrollment, begin the lipid administration and continue it for 96 hours after which time the investigators will repeat bronchoscopy with lavage to assess changes. The lipid administration will cease following the second bronchoscopy. The fluid obtained from lavage combined with serum samples obtained at the time of bronchoscopy will be analyzed for inflammatory mediators and cell counts. Clinical data tracing will include but not be limited to: ventilator days, nutritional status, ICU time, oxygenation and lung compliance, and 30-day mortality.

Full Title of Study: “The Effect of Intravenous Lipid Emulsions on Lung Function in ARDS: A Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: November 2012


  • Drug: ClinOleic 20%
    • 96 hour continuous infusion.
  • Drug: Intralipid 20%
    • 96 hour continuous infusion.

Arms, Groups and Cohorts

  • Experimental: ClinOleic 20%
    • 96 hour continuous infusion.
  • Active Comparator: Intralipid 20%
    • 96 hour continuous infusion.

Clinical Trial Outcome Measures

Primary Measures

  • Bronchoalveolar Lavage Fluid Interleukin-8 Concentrations
    • Time Frame: 96 hours

Secondary Measures

  • Ventilator Days
    • Time Frame: 30 days
  • PaO2:FiO2 Ratio
    • Time Frame: 4 days
    • PaO2:FiO2 ratio at time of 2nd Bronchoalveolar Lavage (BAL) or end of study drug administration.
  • 30 Day Mortality
    • Time Frame: 30 days
  • New Infection
    • Time Frame: 30 days
    • We will use standard clinical criteria including but not limited to: fever, pyuria, new inflitrate on chest x-ray, positive blood cultures, abscess detected on imaging, leukocytosis, and positive skin or soft-tissue cultures to identify presence of new bacterial infections occurring after enrollment.
  • Organ Failures
    • Time Frame: 30 days
  • Biomarkers (C-reactive Protein)
    • Time Frame: 96 hours
  • Hospital Length of Stay
    • Time Frame: 30 days
  • Allergic Reactions
    • Time Frame: 96 hours
  • Hypertriglyceridemia
    • Time Frame: 96 hours
    • Defined as triglyceride level >400

Participating in This Clinical Trial

Inclusion Criteria

  • diagnosed with predisposing condition causing ARDS
  • are mechanically ventilated through an endotracheal tube
  • have enteral feeding access
  • have central venous access
  • have a PaO2:FiO2 ratio of less than 200
  • have bilateral pulmonary infiltrates on chest x-ray

Exclusion Criteria

  • sedation requiring the use of diprivan (after enrollment)
  • a clinical diagnosis of left ventricular failure
  • lung cancer
  • hematologic malignancy
  • severe dyslipidemia
  • condition precluding bronchoscopy including inability to maintain oxygen saturations greater than 90% per pulse oximetry despite conventional mechanical ventilation
  • severe immunosuppression
  • use of NSAIDS within previous 24 hours
  • HIV positive
  • pregnancy
  • hypersensitivity to egg or soybean oil
  • active myocardial infarction
  • acute pancreatitis if complicated by hypertriglyceridemia
  • severe sepsis with 2 or more organ failures

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Methodist Research Institute, Indianapolis
  • Provider of Information About this Clinical Study
    • Principal Investigator: W. Graham Carlos, MD – Methodist Research Institute, Indianapolis
  • Overall Official(s)
    • Chris Naum, MD, Principal Investigator, Indiana Clinic

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.